DFMO, a trypanostatic drug, presents a satisfactory intestinal absorption but its elimination from the blood is rapid so that high doses are necessary to obtain a therapeutic effect. In this study, we propose a strategy to enhance the bioavailability of DFMO by using lipidomimetic derivatives. Three lipidomimetic DFMO derivatives called ODFMO, S-DFMO and Chol-DFMO were designed to reach easily the plasma and to be cleaved preferentially by plasma esterases progressively liberating free DFMO. Chol-DFMO only could be cleaved partially whereas the other compounds appeared to be stable in a reconstituted intestinal medium and mouse plasma. Nevertheless, the use of DFMO derivatives in T. b. brucei experimental chemotherapy appeared as an interesting approach. Thus, ODFMO was trypanocidal in vitro whereas DFMO, the active principle, was only trypanostatic. Nevertheless, this compound did not release DFMO in mouse blood as expected and acted therefore not as a prodrug. Oral treatment using low doses of compound O-DFMO was able to cure 40 % mice while the active principle (eflornithine) administered at 50 fold higher molarity failed to cure any mice. This indicates that compound ODFMO acts by a specific mechanism which remains to be investigated. S-DFMO was less active and Chol-DFMO had no in vitro activity but released small amounts of DFMO in mice, however, too slight to obtain a therapeutic effect. 
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Although this compound was originally designed as an antitumor agent, it has proven to be highly effective against Trypanosoma brucei gambiense infections in man (Doua et al., 1988; Van Nieuwenhove, 1992 Article available at http://www.parasite-journal.org or http://dx.doi.org/10.1051/parasite/1998053239 either suramin or melarsen oxide were found to be effective against acute laboratory model infections of Trypanosoma brucei rbodesiense (Clarkson et al, 1984; Jennings, 1992; Bacchi et al, 1994) , chemotherapy for East African sleeping sickness remains unreliable: drug resistance to arsenical drugs is common and clinical strains refractory to DFMO and diamidines have also been documented (Bayles et al., 1989) . A mean to limit the risk of resistance is to enhance the bioavailability of the active principle in the host in order to limit the duration of treatment and massive dosages. DFMO pre sents a satisfactory intestinal absorption in rats (Levin et al., 1983) . After a single oral dose of 200 mg/kg, the maximum plasma concentration is 100-200 nmol/ml; this concentration is suitable to inhibit ornithine decar boxylase in vitro but the DFMO elimination is rapid since the plasma half life is about 1-2 h. These data explain that high dosages are necessary to obtain a the rapeutic effect. The oral activity of DFMO is an advan tage for mass treatment. In this field, we propose here a strategy to maintain DFMO plasma concentration using lower doses of drug. The use of lipidomimetic derivatives has been previously developed with suc cess in the field of antifilarials using experimental filariasis model (Deverre et al, 1989; Elkihel et al, 1994; Loiseau et al, 1994) . Such derivatives, as prodrugs, can be considered as controlled release systems avoiding rapid elimination of the active principle. The hydro lysis of the prodrugs should be slow to maintain a the rapeutical level of plasma drug concentration. This paper reports the in vitro and in vivo trypanocidal effects of several DFMO derivatives, their in vitro sta bility in the presence of esterases and their potential to liberate DFMO in vivo by a kinetics study. • l,3-dipalmitylthioether-2-acetyl-glycerc)l-DFMO di-trifluo roacetate briefly called S-DFMO. This prodrug possesses a thioether bond between palmityl groups and glycerol. The chemical structure of S-DFMO is reported in Figure 2 . • Cholesterol-DFMO di-trifluoroacetate briefly called Chol-DFMO. Its chemical structure is reported in Figure 3. (Glasgow, U.K.). This strain had been derived from trypanosomes isolated from a wild beast in the Serengeti (Tan zania) in 1966 (Serengeti/66/SVRP/10). It produces a chronic infection in mice, allowing them to survive for at least 30 days.
MATERIALS AND METHODS

IN VITRO EVALUATION
Trypanosomes harvested from infected mice were cul tured in a semi-synthetic medium allowing growth and multiplication for 48 heures without loss of infectivity. The DHT (Drug Incubation Infectivity Test) was used for compound evaluation (Kaminsky et al., 1990) . The culture medium used throughout the study consisted of Minimum Essential Medium (MEM) with Earle's salts and L-glutamine supplemented with 25 mM HEPES, lg/1 additional glucose, 2.2 g/1 NaHC0 3 , 10 ml/1 MEM non essential amino-acids (100 x), 0.2 mM 2-mercaptoethanol, 2 mM sodium pyruvate, 0.1 mM hypoxanthine, 0.016 mM thymidine, 15 % heat-inacti vated horse serum, 100 UI penicillin/ml and 100 pg streptomycin/ml. The culture medium was sterilized by filtration. Blood was collected aseptically from the retro-orbital sinus of infected mice having about 10 K trypanosomes/ml blood, diluted with medium and kept on ice. The trypanosomes were isolated from this suspension by centrifugation at 900 g for 10 min at 4 °C; the supernatant was discarded and trypanosomes were at the top of the pellet. The number of trypanosomes was determined by haemocytometer counting and adjusted to 2 x 10 4 parasites/ml.
The bloodstream forms of T. b. brucei
CMP were maintained in vitro without loss of infectivity for 48 h in the dark at 37 °C in 5 % CO,. The screening was performed in 24-well tissue culture plates (Falcon No 3047). Each well received 1.4 ml culture medium. The wells were then inoculated with 2 x 10 4 trupanosomes in 0.1 ml. Then 10 µl of an adequate dilution/ sus pension of eflornithine or derivatives in water/DMSO was added to each well. Drug concentrations from 4 mM to 0.5 µM were evaluated in duplicate. The number of motile parasites was determined by hae mocytometer counting, using an optical microscope. The effect on multiplication was assessed both visually and in vivo by intraperitoneal injection into naive mice of 0.2 ml of treated trypanosome suspension with drawn from the wells. The mice were checked for parasitaemia weekly for 30 days.
CYTOTOXICITY ASSAY OF THE COMPOUNDS ON MOUSE PERITONEAL MACROPHAGES
Mouse peritoneal macrophages, 5 x 10 6 cells per well, were plated on sterile 96-well plates (Nunc, Paris, France), incubated for 4 hours in an atmosphere of 5 % CO, and 95 % air, at 37 °C. Adherent peritoneal macro phages were washed twice with complete medium and reincubated for 24 hours. Then, 200 µl of medium containing different concentrations of DFMO or its derivatives were added. The viability of cells was determined by the dimethyldiphenyltetrazolium bro mide (MTT) test (Mosmann, 1983) after 24 hours of incubation.
STABILITY OF THE DFMO DERIVATIVES
This study was performed in intestinal reconstituted medium, in medium for trypanosome culture and in infected and noninfected mouse plasma. Preparation of the DFMO derivatives suspensions: 1 mg of DFMO derivative was dissolved in 0.1 ml of CH 2 C1 2 . 0.1 ml of an aqueous solution containing 0.5 % Tween 80 was added. The two phases were mixed by sonication. The suspension was maintained at 37 °C for 20 min to assess the emulsion stability. The stability of DFMO and its derivatives was studied by thin layer chromatography, after in vitro incubations at 37 °C in reconstituted intestinal medium, in medium for trypanosome culture and in infected and nonin fected mouse plasma.
The medium was prepared as follows: 6.8 g of KH,P0 4 were dissolved in 250 ml water. Then 190 ml of 0.2 \ NaOH and MM) ml water were added. 10 g of por cine pancreatin (FU, USP; Merck, Nogent sur Marne, France) including 350 U-FIP proteases/g, 7500 U-FIP lipase/g and 7500 U-FIP amylase/g were mixed with the previous solution. The solution was filled up to 1,000 ml with water and the buffer pH was adjusted to 7.5 ± 0.1 using 0.2N NaOH.
The suspension of DFMO derivative previously prepared was added to 1 ml of intestinal reconstituted medium or medium for trypanosome culture or mouse plasma. The assays were carried out with samples gathered after 15, 30, 60, 120, 180 and 240 minutes of incuba tion. The activities of enzymes in intestinal medium or medium for trypanosome culture or in plasma were blocked for each sample by diluting the sample with two HC1 solution volumes at pH 3. The samples were then freezed, lyophilized and analyzed by thin layer chromatography (Loiseau et al, 1994) .
PLASMA KINETICS OF DFMO
A previous study demonstrated that a chronic trypa nosomiasis in mice modifies the plasma kinetics of DFMO so that we decided to work with the T. b. brucei GVR 35 strain to observe the effect of the chronic try panosomiasis on the DFMO derivatives bioavailability (Loiseau et al., 1997b) . Plasma kinetics was performed on 21-day infected and noninfected mice after treat ment at 2 mmol/kg with DFMO and its derivatives by oral route. Blood samples for drug level detection were collected each 30 min for the first 4 h and each Parasite. 1998, 5, 239-246 241 Mémoire hour for 10 h after treatment with DFMO derivatives. After anesthesia using carbon dioxide, blood was col lected from the retro-orbital sinus into citrated glass pipettes and was centrifuged at 2,200 g for 15 min. Plasma samples were then deproteinized using per chloric acid (100 v/1 v) and centrifuged at 2,200 g for 15 min. The supernatant was kept for assay. DFMO was assayed in plasma following the HPLC method described by Loiseau et al., 1997b .
IN VIVO EVALUATION ON T. B. BRUCEI CMP
The protocol for in vivo evaluation has been previously described (Loiseau et al, 1993) . Mice were infected intraperitoneally with 10 3 bloodstream trypomastigotes suspended in 0.1 ml phosphate buffered saline, pH 7.2. Ten infected mice were used as controls and received only excipient. The other mice were treated by oral route with the DFMO derivatives suspended in 1 % carboxymethylcellulose in sterile water. A drop of Tween 80 was previously added to the powder. The treatment was performed two times per day for six days using at least six mice per dose. The trypanocidal activity was evaluated by the mean survival time of treated mice for each dose. Treatment was considered as successful when the mean survival time exceeded thirty days and the mice remained aparasitaemic.
RESULTS
IN VITRO EVALUATION USING T. B. BRUCEI CMP T his fast strain of T. b. brucei allows to obtain
rapid responses concerning the therapeutic JL effect of DFMO and its derivatives. The trypanosome culture in the semi-defined acellular medium allowed growth from an initial trypanosome number of 5 x 10 4 per well to 20 x 10 4 after a 48 h incubation time. Afterwards, the trypanosome number reached a plateau for 12 h and then dropped. Eflornithine was trypanostatic at 4 and 2 mM after 12 and 24 h of incubation respectively (Fig. 5) . The injec tion of treated trypanosomes to mice did not provoke any infection. Thus, the living parasites have entirely lost their potential for multiplication. A concentration of 1 mM exhibited a trypanostatic effect after 48 h, but after 24 h, this effect was incomplete since the injec tion of treated parasites was fatal for one mouse ( Table 1 ). The eflornithine IC 50 determined after 12, 24, 36 and 48 h was 1,057, 484, 467 and 450 µM respec tively. No morphologic modification was noted during these experiments.
The DFMO derivatives could be assessed up to 200 uM since a precipitate appeared in the wells when higher concentrations were used. O-DFMO killed all parasites at 50 uM after 24 h of incu bation (Fig. 6) . At 10 µM, the trypanocidal effect was com plete after 36 h. A 5 µM concentration was trypanostatic after 24 h of incubation and the parasites treated at this concentration were not able to infect mice. The 50 % lethal concentration (LC50) was 25.1, 6.2 and 4.2 µM after 12, 24 and 36 h incubation time respectively. S-DFMO was less active than O-DFMO since 200 µM was necessary to obtain a trypanocidal effect after 48 h (Fig. 7) . All the parasites were lysed and the injection of treated parasites into mice was not infective. A concentration of 50 µM was trypanostatic after 48 h of incubation and the treated parasites were not infective whereas mice got infected when the incubation time was reduced at 24 h.
Chol-DFMO exhibited no in vitro action at 200 µM. ** Mice were inoculated by intraperitoneal route with 0.2 ml of the trypanosome suspension incubated with the compounds to be tested for 24 or 48 h. *** Activity was defined as the ratio of mice without parasites 30 days post-inoculation to the total number of inoculated mice per batch. **** 0,2 ml of medium for trypanosome culture including the excipient was inoculated into mice by intraperitoneal route. were stable whereas Chol-DFMO was partially degraded in both infected and noninfected mouse plasma.
PLASMA KINETICS OF DFMO DFMO was assayed in plasma after a treatment by oral route at 2 mmol/kg with DFMO and its derivatives. After a treatment with O-DFMO and S-DFMO, no DFMO level could be detected in plasma of 21-day infected and noninfected mice. Plasma samples were collected until 14 h following the treatment. A treat ment carried out in the same conditions with Chol-DFMO allowed to detect small amounts of DFMO around the detection level (5-6 nmol/ml) in the plasma from noninfected mice and 13-15 nmol/ml in plasma from infected mice one hour after treatment by oral route.
IN VIVO EVALUATION
Eflornithine administered ad libitum in drinking water at 2 % for six days cured all the mice and no parasite was found 30 days post-infection. The parasitemia of these mice remained negative throughout the experi ment. Nevertheless, a treatment per os at 2g/kg/day (8,474 µmoles/kg) for six days gave a mean survival time of seven days comparatively to control mice treated only with excipient. Some trypanosomes had a rounded form and their size increased to 25-30 (µm. A treatment carried out in the same conditions but with 84.7 µmoles/kg was without effect on the development of murine trypanosomiasis (Table II) . Concerning the DFMO derivatives, O-DFMO was able to cure 4/10 mice after a treatment at 169.4 pmol/kg whereas DFMO cured 0/10 mice after a dose at 8,474 pmol/kg. S-DFMO and Chol-DFMO were totally inactive in vivo. The ligand 1,3-D-O was also inactive at 169.4 pmol/kg (Table II) .
DISCUSSION AND CONCLUSION
I n vitro, two DFMO derivatives (O-DFMO and S-DFMO) were able to kill the trypanosomes whe reas DFMO itself only inhibited parasite multipli cation. Chol-DFMO was without effect even using high concentrations. This toxic effect of DFMO derivatives toward the parasites was also detected using a cyto toxicity assay on mouse peritoneal macrophages. All the DFMO derivatives remain stable in intestinal reconstituted medium. This result is in favour of an intestinal absorption of the compounds without struc tural modification. In plasma, Chol-DFMO alone is partially degraded. This observation is confirmed in vivo since small amounts of DFMO could be detected after a treatment with Chol-DFMO. These data show that Chol-DFMO only can be considered as a prodrug of DFMO because of its ability to liberate the active principle in the plasma. Nevertheless, the DFMO amounts released from Chol-DFMO in plasma (13-15 µmol/ml) were ten times too low to observe a the rapeutic effect (100-200 nmol/ml). Chol-DFMO was therefore resistant to intestinal esterases but was cleaved slowly in plasma since the maximum concentration of DFMO appeared 1 h after treatment with Chol-DFMO whereas the maximum concentration of DFMO appeared 30 min after a treatment with DFMO by oral route. In vitro experiments did not exhibit degradation products from O-DFMO and S-DFMO and in vivo data demonstrate that there are no intestinal and plasma enzyme systems able to cleave these compounds. O-DFMO and S-DFMO should act themselves by a mecha nism of action that remains to be investigated. Previous pharmacokinetic studies on DFMO in human have shown that maximum plasma concentrations were reached 4 h after treatment with oral dose of 10 mg/kg (Haegele et al, 1981) . DFMO is well absorbed with an average t 1/2 of absorption of 74 min. The kinetics in mice is more rapid since the C max appears 30 min after the treatment (Loiseau et al, 1997b) .
In the recent years, lipidomimetic compounds have been developed to obtain prodrugs able to modify the pharmacokinetics of antiparasitic compounds such as niclosamide, closantel or GABA (Elkihel et al, 1994 ; Loiseau et al, 1997a; Deverre et al., 1989) . The active principle is released from the lipidomimetic ligand by hydrolysis. Such a strategy is valuable for compounds having rapid elimination from plasma compartment because it allows to maintain therapeutic concentra tions of the active principle in plasma. Thus, previous studies showed that the presence of an ester bond bet ween palmityl groups and glycerol allowed the release of the active principle by the action of esterases (Loi seau et al, 1994) . The purpose is here to obtain deri vatives stable in intestinal medium to be cleaved slowly in plasma. The replacement of ester bounds by ether or amide bounds is responsible for a delayed effect of hydrolysis (Elkihel et al, 1994) . Thus, O-DFMO and S-DFMO were designed as DFMO lipidomimetic deri vatives able to resist intestinal esterases. Nevertheless, they were also not cleaved in plasma and act them selves by a specific mechanism of action which remains to be investigated. The most important result from this study is the finding of a compound (O-DFMO) having in vitro trypanocidal properties and a slight in vivo effect. It was not possible to give higher doses because of suspension volume too high for a treatment by oral route in mice. Further studies could be developed on drug formulation in order to have suspension volume allowing treatments using higher doses.
